Aeglea BioTherapeutics, Inc. (AGLE) Social Stream



Aeglea BioTherapeutics, Inc. (AGLE): $12.01

0.97 (+8.79%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

D

Add AGLE to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#246 of 339

in industry

AEGLEA BIOTHERAPEUTICS INC (AGLE) Price Targets From Analysts

Use the tables below to see what analysts covering AEGLEA BIOTHERAPEUTICS INC think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-12-06 4 $15 $11 $13.25 $12.01 10.32%
2022-02-04 4 $15 $9 $12.5 $12.01 4.08%
2022-04-13 4 $20 $9 $12 $12.01 -0.08%
2022-05-05 4 $17 $9 $11.25 $12.01 -6.33%
2022-05-08 4 $17 $7 $10.75 $12.01 -10.49%
2022-05-09 4 $17 $7 $10.5 $12.01 -12.57%
2022-05-11 4 $17 $7 $10.25 $12.01 -14.65%
2022-05-23 4 $17 $4 $9.5 $12.01 -20.9%
2022-06-02 5 $17 $1 $7.25 $12.01 -39.63%
2022-06-03 5 $8 $1 $3.25 $12.01 -72.94%
2022-08-05 4 $3 $1 $1.666 $12.01 -86.13%
2022-10-28 3 $2 $2 $2 $12.01 -83.35%
2023-03-03 5 $3 $1 $1.75 $12.01 -85.43%
2023-07-25 4 $2 $0.9 $1.45 $12.01 -87.93%
2023-08-11 2 $2 $0.9 $1.45 $12.01 -87.93%
2023-08-16 2 $22.5 $12.5 $17.5 $12.01 45.71%
2023-11-10 2 $23 $12.5 $17.75 $12.01 47.79%

The Trend in the Analyst Price Target


AGLE's average price target has moved up $3.61 over the prior 33 months.

AGLE reports an average of 438.04% for its upside potential over the past 49 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2023-01-06 5 3.0 1.0 1.875 0.500 275%
2023-03-03 5 3.0 1.0 1.875 0.394 375.89%
2023-08-16 2 22.5 12.5 17.500 0.462 3687.88%
2023-08-16 2 0.9 0.5 0.700 0.462 51.52%
2023-11-10 2 23.0 12.5 17.750 9.490 87.04%

AGLE Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
2 1 0 1 0 0 2

The Trend in the Broker Recommendations


Over the past 46 months, AGLE's average broker recommendation rating worsened by 0.67.

The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.

  • In the context of all US stocks, AEGLEA BIOTHERAPEUTICS INC's average analyst price target is higher than 159.82% of them.
  • In the context of all US stocks, AEGLEA BIOTHERAPEUTICS INC's upside potential (average analyst target price relative to current price) is higher than 240.22% of them.
  • In the context of Healthcare stocks, AEGLEA BIOTHERAPEUTICS INC's number of analysts covering the stock is higher than 400.25% of them.
  • In the context of stocks in the small market cap category, AEGLEA BIOTHERAPEUTICS INC's variance in analysts' estimates is lower than -1691.3% of them.

In the Pharmaceutical Products industry, CTMX, SYBX, and ACRS are the three stocks most similar to AEGLEA BIOTHERAPEUTICS INC regarding the price target and analyst recommendation information presented here.

What is the outlook for AGLE? Use POWR Ratings for clearer insight into price direction.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!